Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes: a randomized, double blind, placebo-controlled trial

Journal of Diabetes & Metabolic Disorders

Shima Jazayeri²  Banafsheh Golestan¹  Iraj Heydari³  Farzad Shidfar²  Neshat Rezaee²  Soroush Seifirad⁴  Shahryar Eghtesadi²  Hoda Zahedi⁵ 

[1]Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

[2]Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

[3]Institute of Endocrinology and Metabolism, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran

[4]Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

[5]Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular -Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

关键词: Inflammation;    Oxidative stress;    Blood glucose;    Diabetes mellitus type 2;    Coenzyme Q10;   

Others  :  1136174
DOI  :  10.1186/s40200-014-0081-6

 received in 2014-01-07, accepted in 2014-07-13,  发布年份 2014

【 摘 要 】

Background

Low grade inflammation and oxidative stress are the key factors in the pathogenesis and development of diabetes and its complications. Coenzyme Q10 (CoQ10) is known as an antioxidant and has a vital role in generation of cellular energy providing. This study was undertaken to evaluate the effects of CoQ10 supplementation on lipid profiles and glycemic controls in patients with diabetes.

Methods

Fifty patients with diabetes were randomly allocated into two groups to receive either 150 mg CoQ10 or placebo daily for 12 weeks. Before and after supplementation, fasting venous blood samples were collected and lipid profiles containing triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) and glycemic indices comprising of fasting plasma glucose (FPG), insulin and hemoglobin A₁C (HbA₁C) were measured. Insulin resistance was calculated using HOMA-IR index.

Results

Forty patients completed the study. After intervention FPG and HbA₁C were significantly lower in the CoQ10 group compared to the placebo group, but there were no significant differences in serum insulin and HOMA-IR between the two groups. Although total cholesterol did not change in the Q10 group after supplementation, triglyceride and HDL-C significantly decreased and LDL-C significantly increased in the CoQ10 group.

Conclusion

The present study showed that treatment with Q10 may improve glycemic control with no favorable effects on lipid profiles in type 2 patients with diabetes.

Trial registration

IRCT registry number: IRCT138806102394N1 webcite

【 授权许可】

   
2014 Zahedi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ghorbanihaghjo A, Kolahi S, Seifirad S, Rashtchizadeh N, Argani H, Hajialilo M, Khabazi A, Alizadeh S, Bahreini E: Effect of fish oil supplements on serum paraoxonase activity in female patients with rheumatoid arthritis: a double-blind randomized controlled trial. Arch Iran Med 2012, 15:549-552.
• [2]Chew G, Watts G: Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the ‘recoupling hypothesis’. QJM 2004, 97:537-548.
• [3]Wang XL, Rainwater DL, Mahaney MC, Stocker R: Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons. Am J Clin Nutr 2004, 80:649-655.
• [4]Lim SC, Lekshminarayanan R, Goh SK, Ong YY, Subramaniam T, Sum CF, Ong CN, Lee BL: The effect of coenzyme Q10 on microcirculatory endothelial function of subjects with type 2 diabetes mellitus. Atherosclerosis 2008, 196:966-969.
• [5]Littarru GP, Tiano L: Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 2007, 37:31-37.
• [6]Kocharian A, Shabanian R, Rafiei-Khorgami M, Kiani A, Heidari-Bateni G: Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiol Young 2009, 19:501-506.
• [7]Lenaz G, Fato R, Castelluccio C, Cavazzoni M, Estornell E, Huertas J, Pallotti F, Parenti Castelli G, Rauchova H: An updating of the biochemical function of coenzyme Q in mitochondria. Mol Aspects Med 1994, 15:s29-s36.
• [8]Bradley R, Oberg EB, Calabrese C, Standish LJ: Algorithm for complementary and alternative medicine practice and research in type 2 diabetes. J Altern Complement Med 2007, 13:159-176.
• [9]Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella A, Butterfield DA: Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci 2005, 233:145-162.
• [10]Emerit J, Edeas M, Bricaire F: Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004, 58:39-46.
• [11]Bliznakov EG: Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case–a modern Pandora's box. Biomed Pharmacother 2002, 56:56-59.
• [12]Lamson DW, Plaza SM: Mitochondrial factors in the pathogenesis of diabetes: a hypothesis for treatment. Altern Med Rev 2002, 7:94-111.
• [13]Salles JE, Moisés VA, Almeida DR, Chacra AR, Moisés RS: Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10. Diabetes Res Clin Pract 2006, 72:100-103.
• [14]Suzuki S, Hinokio Y, Ohtomo M, Hirai M, Hirai A, Chiba M, Kasuga S, Satoh Y, Akai H, Toyota T: The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 1998, 41:584-588.
• [15]Lim S, Tan H, Goh S, Subramaniam T, Sum C, Tan I, Lee B, Ong C: Oxidative burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q10. Diabet Med 2006, 23:1344-1349.
• [16]Modi K, Santani D, Goyal R, Bhatt P: Effect of coenzyme Q10 on catalase activity and other antioxidant parameters in streptozotocin-induced diabetic rats. Biol Trace Elem Res 2006, 109:25-33.
• [17]Sena CM, Nunes E, Gomes A, Santos MS, Proenca T, Martins MI, Seica RM: Supplementation of coenzyme Q10 and alpha-tocopherol lowers glycated hemoglobin level and lipid peroxidation in pancreas of diabetic rats. Nutr Res 2008, 28:113-121.
• [18]Kunitomo M, Yamaguchi Y, Kagota S, Otsubo K: Beneficial effect of coenzyme Q10 on increased oxidative and nitrative stress and inflammation and individual metabolic components developing in a rat model of metabolic syndrome. J Pharmacol Sci 2008, 107:128-137.
• [19]Playford DA, Watts GF, Croft KD, Burke V: Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003, 168:169-179.
• [20]Chew GT, Watts GF, Davis TM, Stuckey BG, Beilin LJ, Thompson PL, Burke V, Currie PJ: Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008, 31:1502-1509.
• [21]Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD: Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002, 56:1137-1142.
• [22]Witting PK, Pettersson K, Letters J, Stocker R: Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice. Free Radic Biol Med 2000, 29:295-305.
• [23]Littarru GP, Tiano L: Clinical aspects of coenzyme Q10: an update. Nutrition 2010, 26:250-254.
• [24]Quiles JL, Ochoa JJ, Battino M, Gutierrez-Rios P, Nepomuceno EA, Frias ML, Huertas JR, Mataix J: Life-long supplementation with a low dosage of coenzyme Q10 in the rat: effects on antioxidant status and DNA damage. Biofactors 2005, 25:73-86.
• [25]Eriksson JG, Forsen TJ, Mortensen SA, Rohde M: The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 1999, 9:315-318.
• [26]Henriksen JE, Andersen CB, Hother-Nielsen O, Vaag A, Mortensen SA, Beck-Nielsen H: Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet Med 1999, 16:312-318.
• [27]Coldiron AD Jr, Sanders RA, Watkins JB 3rd: Effects of combined quercetin and coenzyme Q(10) treatment on oxidative stress in normal and diabetic rats. J Biochem Mol Toxicol 2002, 16:197-202.
• [28]Taylor AA: Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol Metab Clin North Am 2001, 30:983-997.
• [29]Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140-1142.
• [30]Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, Beckles GL, Saaddine J, Gregg EW, Williamson DF: Type 2 diabetes among North adolescents: An epidemiologic health perspective. J Pediatr 2000, 136:664-672.
• [31]Lee SK, Lee JO, Kim JH, Kim N, You GY, Moon JW, Sha J, Kim SJ, Lee YW, Kang HJ, Park SH, Kim HS: Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPARalpha induction in 3 T3-L1 preadipocytes. Cell Signal 2012, 24:2329-2336.
• [32]Suckling KE, Jackson B: Animal models of human lipid metabolism. Prog Lipid Res 1993, 32:1-24.
• [33]Ruotolo G, Ericsson CG, Tettamanti C, Karpe F, Grip L, Svane B, Nilsson J, de Faire U, Hamsten A: Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998, 32:1648-1656.
• [34]Klopotek A, Hirche F, Eder K: PPAR gamma ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2. Exp Biol Med (Maywood) 2006, 231:1365-1372.
• [35]Schroeder MM, Belloto RJ Jr, Hudson RA, McInerney MF: Effects of antioxidants coenzyme Q10 and lipoic acid on interleukin-1 beta-mediated inhibition of glucose-stimulated insulin release from cultured mouse pancreatic islets. Immunopharmacol Immunotoxicol 2005, 27:109-122.
• [36]Kajimoto Y, Kaneto H: Role of oxidative stress in pancreatic beta-cell dysfunction. Ann N Y Acad Sci 2004, 1011:168-176.
• [37]Pfutzner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lubben G, Forst T: Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004, 27:682-687.
• [38]Seifirad S, Ghaffari A, Amoli MM: The antioxidants dilemma: are they potentially immunosuppressants and carcinogens? Front. Physiol 2014, 5:245. doi:10.3389/fphys.2014.00245